United Therapeutics (UTHR) Free Cash Flow (2009 - 2026)

United Therapeutics has disclosed Free Cash Flow across 18 years of filings, most recently posting $362.5 million for Q1 2026.

• Free Cash Flow for Q1 2026 came in at $362.5 million, down 12.44% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.4 billion (up 2.01% YoY), and the FY2025 annual result was $1.4 billion, up 10.73% from the prior year.
• Free Cash Flow came in at $362.5 million for Q1 2026 at United Therapeutics, up from $322.1 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $607.0 million in Q3 2025 to a low of $61.6 million in Q2 2023.
• The 5-year median for Free Cash Flow is $280.5 million (2023), against an average of $266.1 million.
• Across the five-year window, Free Cash Flow jumped 565.0% in 2024 and sank 57.21% in 2025, its largest moves.
• United Therapeutics' Free Cash Flow stood at $88.7 million in 2022, then dropped by 18.83% to $72.0 million in 2023, then surged by 565.0% to $478.8 million in 2024, then slumped by 32.73% to $322.1 million in 2025, then climbed by 12.54% to $362.5 million in 2026.
• The last three Free Cash Flow figures came in at $362.5 million (Q1 2026), $322.1 million (Q4 2025), and $607.0 million (Q3 2025), per Business Quant data.